The investigators developed a 16-plex nanopore sequencing panel to screen host pharmacogenetic variants that may influence trough concentrations and treatment-associated toxicities for second-line anti-tubercular agents. The panel targets 23 variants: 21 with clinical validation and 2 predicted actionable variants. Targeted drugs included linezolid, bedaquiline, clofazimine, moxifloxacin, and ethambutol. The assay was intended for scalable, pre-treatment screening and compatible with noninvasive sampling (saliva).
To benchmark analytical performance, the team sequenced DNA from 50 Coriell samples derived from the 1000 Genomes Project. These reference samples were used to compare panel results against Illumina sequencing (as described in the source). The benchmarking step established baseline accuracy and enabled evaluation of variant calling performance before clinical application to patient-derived saliva.
After analytical benchmarking, the panel was applied to saliva samples from 202 individuals undergoing treatment for drug-resistant tuberculosis in India. Sequencing was performed on a MinION Mk1C (R10.4) nanopore device. The study combined sequencing data with measured plasma trough concentrations and recorded toxicity events to explore genotype–phenotype relationships for drug exposure and adverse effects. Data processing and variant calling used the authors’ in‑house analysis pipelines.
In saliva samples the multiplex panel achieved high sequencing depth with a reported median coverage of 3,609X across targets. High coverage supported confident detection of the targeted variants in a noninvasive specimen type. The source reports that the panel reliably detected the pharmacogenetic variants of interest in this clinical saliva cohort.
The authors evaluated associations between genotype and pharmacokinetic or toxicity outcomes stratified by drug and dosing subgroup. For moxifloxacin, a notable finding in a subgroup receiving high-dose moxifloxacin (800 mg daily) was an association between UGT1A1 rs3755319 A>C and higher plasma trough concentrations. Specifically, heterozygotes and homozygous alternate carriers showed higher troughs compared with reference genotype in this subgroup, with reported nominal statistical significance.
In toxicity analyses, UGT1A1 rs4148323 G>A heterozygotes had higher rates of moxifloxacin-associated toxicity than wild-type carriers (reported percentages noted in the source). These observations were reported as suggestive genotype–phenotype trends reaching nominal significance in distinct subsets rather than as cohort-wide definitive findings.
For linezolid, the authors report dose-dependent genotype associations. Among patients whose linezolid dose was reduced to 300 mg, homozygous alternate carriers of ABCB1 rs2032582 A>C (7 of 98 in that subgroup) had significantly lower Cmin compared with wild-type and heterozygotes; these relationships were not observed at standard dosing.
Regarding toxicity, linezolid-associated adverse events were more frequent in carriers of ABCB1 rs1128503 A>G heterozygotes compared with homozygous reference individuals (reported proportions in the source). These signals were presented as nominally significant and observed within particular clinical subsets rather than across all treated patients.
The study demonstrates that a portable, saliva-based nanopore sequencing approach can reliably detect pharmacogenetic variants relevant to second-line anti-tubercular therapy. High sequencing depth in saliva and the ability to run assays on a MinION device support feasibility for point-of-care or decentralized screening. The reported genotype–phenotype trends suggest the panel could inform pre-treatment risk stratification for altered drug exposure or increased toxicity potential.
However, the source frames the reported associations as suggestive and reaching nominal significance in specific subgroups; broader validation, prospective clinical utility studies, and details on sensitivity, specificity, and reproducibility for all targets beyond the benchmarking phase were not reported in the source. Implementation details such as clinical decision thresholds, integration into dosing algorithms, or cost-effectiveness analyses were not provided in the article text.
Ethical approvals for the clinical work were obtained from the ethics committee of PD Hinduja Hospital (Mumbai), Johns Hopkins University, and the Institute of Bioinformatics (Bangalore). The authors state that all necessary participant consent and institutional approvals were in place. Data produced in the study are available upon reasonable request to the authors. Funding sources listed in the source include the Department of Biotechnology, the Department of Science and Technology, and National Institute of Allergy and Infectious Diseases grants cited by grant number in the original article.
Overall, the reported work provides a technical proof-of-concept and initial clinical application of a saliva-based nanopore pharmacogenomic panel in patients treated for drug-resistant tuberculosis, with several genotype–phenotype signals that merit further validation in larger or prospective cohorts.